Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

3.15
+0.25008.62%
Post-market: 3.150.0005+0.02%19:59 EDT
Volume:18.81M
Turnover:59.42M
Market Cap:2.78B
PE:-5.48
High:3.32
Open:2.95
Low:2.95
Close:2.90
Loading ...

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
03 Jun

ImmunityBio Inc. to Attend ASCO Annual Meeting 2025 in Chicago

Reuters
·
03 Jun

Unusually active option classes on open June 2nd

TIPRANKS
·
02 Jun

ImmunityBio Inc. Receives FDA Expanded Access Authorization for ANKTIVA Cancer BioShield™ to Treat Lymphopenia in Solid Tumor Patients

Reuters
·
02 Jun

Immunitybio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With Anktiva®, the Cancer Bioshield™ Platform, in Patients With Solid Tumors

THOMSON REUTERS
·
02 Jun

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 May

ImmunityBio to launch Cancer BioShield in the Middle East

TIPRANKS
·
27 May

Immunitybio, Saudi Arabia’s Ministry of Investment, Kfshrc, and Kaimrc Sign Strategic Memorandum of Understanding to Launch Cancer Bioshield™ Platform in the Middle East

THOMSON REUTERS
·
27 May

ImmunityBio Raised to Overweight From Neutral by Piper Sandler

Dow Jones
·
20 May

Immunitybio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global

Reuters
·
13 May

ImmunityBio Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
13 May

BUZZ-ImmunityBio rises on Q1 revenue beat

Reuters
·
12 May

Immunitybio Shares up 17.2% After Q1 Revenue Beat

THOMSON REUTERS
·
12 May

Sector Update: Health Care Stocks Advance Premarket Monday

MT Newswires Live
·
12 May

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 May

ImmunityBio Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
12 May

Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss

MT Newswires Live
·
12 May

ImmunityBio Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $16.52M Beat $16.02M Estimate

Benzinga
·
12 May

Press Release: ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

Dow Jones
·
12 May